ACTRN12606000192583
Completed
Phase 2
A randomised, double blind, placebo controlled, Phase IIa study of the safety of R-flurbiprofen administered as a topical gel to patients with a history of non-melanoma skin cancer
PharmaQest Pty Ltd0 sites40 target enrollmentMay 24, 2006
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-melanoma skin cancer
- Sponsor
- PharmaQest Pty Ltd
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must have had at least one non\-melanoma skin cancer in the past 5 years.
Exclusion Criteria
- •Any significant medical disorder;Current use of NSAIDs (and unwilling to cease use).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Fulvestrant +/- vandetanib in advanced aromatase inhibitor resistant breast cancer.Metastatic breast cancer that has become resistant to aromatase inhibitor therapyTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-001208-23-GBVelindre NHS Trust
Active, not recruiting
Phase 1
A comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancerGlioblastomaMedDRA version: 19.0 Level: PT Classification code 10018336 Term: Glioblastoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-003138-17-GBF. Hoffmann-La Roche Ltd296
Active, not recruiting
Phase 1
Clinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancerGlioblastomaMedDRA version: 19.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-003138-17-SEF. Hoffmann-La Roche Ltd300
Active, not recruiting
Phase 1
A comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancerGlioblastomaMedDRA version: 18.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-003138-17-LVF. Hoffmann-La Roche Ltd300
Active, not recruiting
Phase 1
A comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancerEUCTR2012-003138-17-ATF. Hoffmann-La Roche Ltd300